A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

Stopped recruiting/enrolling participants has halted prematurely but potentially will resume Oct

Conditions

• Irritable Bowel Syndrome

Interventions

• DRUG: 0.075 mg RVX-100
• DRUG: 0.125 mg RVX-100
• DRUG: 0.250 mg RVX-100
• DRUG: placebo

Sponsor

Revogenex, Inc.